TLR10 (CD290) Is a Regulator of Immune Responses in Human Plasmacytoid Dendritic Cells
The Journal of Immunology · 2024
DOI: 10.4049/jimmunol.2200468 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Pratik Deb und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers School of Graduate Studies, Newark, NJ. Hauptthemen laut MEDLINE: Dendritic Cells, Suppressor of Cytokine Signaling 3 Protein, Interferon Regulatory Factor-7, STAT3 Transcription Factor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), NCRR NIH HHS.
Abstract (Originalsprache)
TLRs are the most thoroughly studied group of pattern-recognition receptors that play a central role in innate immunity. Among them, TLR10 (CD290) remains the only TLR family member without a known ligand and clearly defined functions. One major impediment to studying TLR10 is its absence in mice. A recent study on TLR10 knock-in mice demonstrated its intrinsic inhibitory role in B cells, indicating that TLR10 is a potential drug target in autoimmune diseases. In this study, we interrogated the expression and function of TLR10 in human plasmacytoid dendritic cells (pDCs). We have seen that primary human pDCs, B cells, and monocytes constitutively express TLR10. Upon preincubation with an anti-TLR10 Ab, production of cytokines in pDCs was downregulated in response to stimulation with DNA and RNA viruses. Upon further investigation into the possible mechanism, we documented phosphorylation of STAT3 upon Ab-mediated engagement of TLR10. This leads to the induction of inhibitory molecule suppressor of cytokine signaling 3 (SOCS3) expression. We have also documented the inhibition of nuclear translocation of transcription factor IFN regulatory factor 7 (IRF7) in pDCs following TLR10 engagement. Our data provide the (to our knowledge) first evidence that TLR10 is constitutively expressed on the surface of human pDCs and works as a regulator of their innate response. Our findings indicate the potential of harnessing the function of pDCs by Ab-mediated targeting of TLR10 that may open a new therapeutic avenue for autoimmune disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rutgers School of Graduate Studies, Newark, NJ.
- Department of Pathology, Immunology and Laboratory Medicine, Rutgers New Jersey Medical School, Newark, NJ.
- Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ.
- Department of Otorhinolaryngology, Rutgers New Jersey Medical School, Newark, NJ.
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, WI.
- University of Illinois College of Medicine, Peoria Campus, Peoria, IL.
ORCID-Profile: Evelyne Kalyoussef, Nicholas J Hess, Richard I Tapping, Patricia Fitzgerald-Bocarsly
Förderung
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- NCRR NIH HHS
- NIH HHS
Zitieren
APA
Deb, P., Singh, S., Kalyoussef, E., Hess, N. J., Tapping, R. I., & Fitzgerald-Bocarsly, P. (2024). TLR10 (CD290) Is a Regulator of Immune Responses in Human Plasmacytoid Dendritic Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2200468
Vancouver
Deb P, Singh S, Kalyoussef E, Hess NJ, Tapping RI, Fitzgerald-Bocarsly P. TLR10 (CD290) Is a Regulator of Immune Responses in Human Plasmacytoid Dendritic Cells. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2200468
BibTeX
@article{Deb2024,
author = {Deb, Pratik and Singh, Sukhwinder and Kalyoussef, Evelyne and Hess, Nicholas J and Tapping, Richard I and Fitzgerald-Bocarsly, Patricia},
title = {TLR10 (CD290) Is a Regulator of Immune Responses in Human Plasmacytoid Dendritic Cells},
journal = {The Journal of Immunology},
year = {2024},
doi = {10.4049/jimmunol.2200468}
}
EUVIMED